Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type ALK, Wild type EGFR status confers therapeutic sensitivity to Cisplatin, Pembrolizumab, Pemetrexed in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations